Their Piper Jaffrey presentation is at 10:30 EST and they put the presentation slides on the investor relations page of the santarus website.
The trend lines for Glumetza and Cycloset still look excellent. I am hopeful AGAIN of a nice earnings number. They will have to pay the $1,542,000 PDUFA fee to file for the Uceris NDA, but everything else should in line on the expense side.
I can't conjure what that would be. I don't think they want to send it down to the trial court for anything other than a determination of damages if necessary. So I think a decision will be made by this court on the law as the facts really aren't in dispute. I also believe the court does not want a murky decision on the obvsiousness issue. One of the themes that has struck me as giving some factual cover is that a very large, sophisticated pharma company whose patent is cited as essential prior art in the patent prosecution and by the parties to the lawsuit thought it should receive a license from SNTS to distribute Zegerid rather than disregard SNTS's patent.